A genome-wide association study of antidepressant-induced mania

Clement C. Zai, Alessio Squassina, Arun K. Tiwari, Claudia Pisanu, Marco Pinna, Federica Pinna, Anna Meloni, Pasquale Paribello, Bernardo Carpiniello, Leonardo Tondo, Mark A. Frye, Joanna M. Biernacka, Brandon J. Coombes, James L. Kennedy, Mirko Manchia

Research output: Contribution to journalArticlepeer-review

Abstract

Antidepressant-induced mania (AIM) is a side effect of antidepressant treatment that is characterized by mania or hypomania after the start of medication. It is likely polygenic, but its genetic component remains largely unexplored. We aim to conduct the first genome-wide association study of AIM in 814 bipolar disorder patients of European ancestry. We report no significant findings from our single-marker or gene-based analyses. Our polygenic risk score analyses also did not yield significant results with bipolar disorder, antidepressant response, or lithium response. Our suggestive findings on the hypothalamic-pituitary-adrenal axis and the opioid system in AIM require independent replications.

Original languageEnglish (US)
Article number110800
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume127
DOIs
StatePublished - Dec 20 2023

Keywords

  • Antidepressant-induced mania
  • Bipolar disorder
  • Depression
  • Genome-wide association study
  • Pharmacogenetics

ASJC Scopus subject areas

  • Pharmacology
  • Biological Psychiatry

Fingerprint

Dive into the research topics of 'A genome-wide association study of antidepressant-induced mania'. Together they form a unique fingerprint.

Cite this